- Home
- ANGX vs AQST Comparison
ANGX vs AQST Comparison
Compare ANGX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGX
- AQST
- Stock Information
- Founded
- ANGX 2013
- AQST 2004
- Country
- ANGX United States
- AQST United States
- Employees
- ANGX N/A
- AQST N/A
- Industry
- ANGX Movies/Entertainment
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- ANGX Consumer Discretionary
- AQST Health Care
- Exchange
- ANGX Nasdaq
- AQST Nasdaq
- Market Cap
- ANGX 960.8M
- AQST 809.3M
- IPO Year
- ANGX N/A
- AQST 2018
- Fundamental
- Price
- ANGX $5.34
- AQST $5.80
- Analyst Decision
- ANGX Strong Buy
- AQST Strong Buy
- Analyst Count
- ANGX 1
- AQST 7
- Target Price
- ANGX $14.00
- AQST $10.00
- AVG Volume (30 Days)
- ANGX 517.5K
- AQST 2.8M
- Earning Date
- ANGX 11-13-2025
- AQST 11-05-2025
- Dividend Yield
- ANGX N/A
- AQST N/A
- EPS Growth
- ANGX N/A
- AQST N/A
- EPS
- ANGX N/A
- AQST N/A
- Revenue
- ANGX $242,655,179.00
- AQST $43,397,000.00
- Revenue This Year
- ANGX $197.90
- AQST N/A
- Revenue Next Year
- ANGX $19.95
- AQST $51.39
- P/E Ratio
- ANGX N/A
- AQST N/A
- Revenue Growth
- ANGX 110.21
- AQST N/A
- 52 Week Low
- ANGX $3.77
- AQST $2.12
- 52 Week High
- ANGX $60.00
- AQST $7.55
- Technical
- Relative Strength Index (RSI)
- ANGX N/A
- AQST 46.09
- Support Level
- ANGX N/A
- AQST $5.21
- Resistance Level
- ANGX N/A
- AQST $5.78
- Average True Range (ATR)
- ANGX 0.00
- AQST 0.44
- MACD
- ANGX 0.00
- AQST -0.07
- Stochastic Oscillator
- ANGX 0.00
- AQST 37.05
About ANGX Angel Studios Inc. Class A Common Stock
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.